STAT3及其相关因子在白藜芦醇抗原发性脑肿瘤作用中的意义分析
|
摘要
目的：在髓母细胞瘤细胞系UW228-3细胞和胶质母细胞瘤细胞系LN-18细胞中研究白藜芦醇(Resveratrol, Res)对STAT3及其相关因子LIF、c-Myc、Survivin、Cox-2、CyclinD1、Bcl-2表达情况的影响,以及STAT3和细胞的生长、分化、凋亡与耐药之间的关系,探讨白藜芦醇在抗髓母细胞瘤和胶质母细胞瘤作用中的分子机制,为改善髓母细胞瘤和胶质母细胞瘤的临床化学治疗现状提供新的实验室指标和理论根据。
方法：人髓母细胞瘤细胞系UW228-3细胞和胶质母细胞瘤细胞系LN-18细胞分别培养于含10%胎牛血清的DMEM (Dulbecco's Modified Eagle's Medium)培养液中,以5×104/ml的初始细胞密度接种于Φ60mm和Φ100mm的培养皿中,24小时后用100μM白藜芦醇进行处理。将白藜芦醇溶解于二甲基亚砜(DMSO,demethylsulfoxide)溶液中,以5mM的浓度储存,使用前稀释到100μM。用100μM白藜芦醇(resveratrol, Res),处理细胞48小时,观察其对细胞的作用效果。为便于观察细胞形态学特征和进行免疫细胞化学(ICC)染色,将无菌盖玻片预先置于培养皿底部制备细胞爬片,待取出时用100%冷丙酮进行固定。同时收集细胞悬液并离心沉淀以用于RNA和蛋白质的提取。采用免疫细胞化学、RT-PCR和Western-blotting等方法系统检测髓母细胞瘤细胞系UW228-3细胞和胶质母细胞瘤细胞系LN-18细胞中STAT3及其相关因子LIF、c-Myc、Survivin、Cox-2、CyclinD1和Bcl-2在100μM白藜芦醇处理前后表达水平的改变、细胞内的分布状况及其与分化和凋亡的关系。
结果：1)用100μM白藜芦醇处理细胞48h时后,对白藜芦醇敏感的髓母细胞瘤细胞系UW228-3细胞形态发生明显改变,而白藜芦醇并不能引起胶质母细胞瘤细胞系LN-18细胞形态的变化。2)在髓母细胞瘤细胞系UW228-3细胞中,白藜芦醇可以下调STAT3的表达水平并且使其核易位程度明显减少,而在胶质母细胞瘤细胞系LN-18细胞中,白藜芦醇可使STAT3发生核易位但对STAT3表达水平的影响很小。3)白藜芦醇可以明显上调髓母细胞瘤细胞系UW228-3细胞中LIF的表达水平,而对胶质母细胞瘤细胞系LN-18细胞中LIF表达水平的影响甚小。4)在髓母细胞瘤细胞系UW228-3细胞中,100μM白藜芦醇可不同程度地下调c-Myc、Survivin、Cox-2和CyclinD1的表达水平,上调Bcl-2的表达水平,而在胶质母细胞瘤细胞系LN-18细胞中100μM白藜芦醇对c-Myc、Survivin、Cox-2、CyclinD1和Bcl-2表达水平皆无明显影响。
结论：1)本研究证实100μtM白藜芦醇在诱导髓母细胞瘤细胞系UW228-3细胞发生分化和调亡的同时,抑制了STAT3通路的活化,而在胶质母细胞瘤细胞系LN-18细胞中白藜芦醇未呈现其抗肿瘤作用但是STAT3发生核易位。2)髓母细胞瘤细胞系UW228-3细胞对白藜芦醇的作用较敏感,而胶质母细胞瘤细胞系LN-18细胞对白藜芦醇的作用则具有耐药性。3)本研究进一步证实了对STAT3信号转导通路的抑制是白藜芦醇抗原发性脑肿瘤作用的重要分子机制。
Objective:To study the effect of STAT3 and its related factors LIF, c-Myc, Survivin, Cox-2, CyclinD1, Bcl-2 in resveratrol anti-medullo-blastoma cell line UW228-3 cells and anti-glioblastoma cell line LN-18 cells respectively, analyzing the relationship of STAT3 on cell growth, differentiation, apoptosis and drug resistance, investigating the molecular mechanism of resveratrol anti-medulloblastoma and anti-glioblastoma, so as to provide a new laboratory evidence and theoretic basis for improving the current clinical chemotherapy status of medulloblastoma and glioblastoma.
Methods:Human medulloblastoma cell line UW228-3 cells and glioblastoma cell line LN-18 cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium) culture medium containing 10% Fetal Bovine Serum (FBS). The cells (5×104/ml) were plated toΦ60mm andΦ100mm dishes and incubated for 24 hours before further experiments. Resveratrol was dissolved in dimethylsulfoxide to a stock concentration of 5mM and diluted with culture medium to an optimal working concentration of 100μM just before use. The cells were treated with resveratrol (100μM) for 48 hours, to observe the effect on the cells. Put sterilized cover slips in the dishes before cell seeding for cell morphology observation and immunocytochemistry (ICC) staining were performed. After above treatments, cover slips were collected and fixed with 100% cold acetone. Meanwhile, Cell suspension was collected and centrifuged to extract RNA and protein.Immunocyrochemistry (ICC) staining, RT-PCR Western blotting and other methods were used to analyze the expression levels and their intracellular distribution of STAT3 and its related factors LIF, c-Myc, Survivin, Cox-2, CyclinD1 and Bcl-2 in medulloblastoma cell line UW228-3 cells and glioblastoma cell line LN-18 cells with and without resveratrol treatment, in order to explore the expression levels, the distribution in intracellular and the correlation between STAT3 and its related factors LIF,c-Myc, Survivin, Cox-2, CyclinD1, Bcl-2 and differentiation, as well as apoptosis.
Results:1) On resveratrol-sensitive medulloblastoma line UW228-3 cells, the cell morphology changes apparent with resveratrol(100μM) treatment for 48 hours, but no obvious morphological changes were observed on glioblastoma cell line LN-18 cells with resveratrol (100μM) treatment for 48 hours.2) In the medulloblastoma cell line UW228-3 cells, resveratrol reduced the expression of STAT3 and its nuclear translocation levels decreased, whereas in glioblastoma cell line LN-18 cells, resveratrol can induce STAT3 nuclear translocation, but not much change on STAT3 expression levels.3) The expression of LIF significantly up-regulated in medulloblastoma cell line UW228-3 cells with resveratrol(100μM) treatment, whereas in glioblastoma cell line LN-18 cells, the expression of LIF did not change much.4) The expression of c-Myc, Survivin, Cox-2, CyclinD1 was down-regulated, Bcl-2 expression levels were significantly up-regulated in medulloblastoma cell line UW228-3 cells with resveratrol (100μM) treatment; c-Myc, Survivin, Cox-2, CyclinD1, Bcl-2 were no significant changes in expression levels in glioblastoma cell line LN-18 cells with and without resveratrol(100μM) treatment.
Conclusions:1) This study demonstrated that resveratrol(100μM) induced medulloblastoma cell line UW228-3 cells differentiation and apoptosis, while inhibited the STAT3 pathway activation; whereas in glioblastoma cell line LN-18 cells, resveratrol did not show its anti-tumor effect but the STAT3 nuclear translocation occured.2) The medulloblastoma cell line UW228-3 cells were sensitive to resveratrol, while the glioblastoma cell line LN-18 cells was resistant to resveratrol.3) The study further confirmed that the inhibition of STAT3 signaling pathway is an important anti-primary brain tumor molecular mechanism of resveratrol.
方法：人髓母细胞瘤细胞系UW228-3细胞和胶质母细胞瘤细胞系LN-18细胞分别培养于含10%胎牛血清的DMEM (Dulbecco's Modified Eagle's Medium)培养液中,以5×104/ml的初始细胞密度接种于Φ60mm和Φ100mm的培养皿中,24小时后用100μM白藜芦醇进行处理。将白藜芦醇溶解于二甲基亚砜(DMSO,demethylsulfoxide)溶液中,以5mM的浓度储存,使用前稀释到100μM。用100μM白藜芦醇(resveratrol, Res),处理细胞48小时,观察其对细胞的作用效果。为便于观察细胞形态学特征和进行免疫细胞化学(ICC)染色,将无菌盖玻片预先置于培养皿底部制备细胞爬片,待取出时用100%冷丙酮进行固定。同时收集细胞悬液并离心沉淀以用于RNA和蛋白质的提取。采用免疫细胞化学、RT-PCR和Western-blotting等方法系统检测髓母细胞瘤细胞系UW228-3细胞和胶质母细胞瘤细胞系LN-18细胞中STAT3及其相关因子LIF、c-Myc、Survivin、Cox-2、CyclinD1和Bcl-2在100μM白藜芦醇处理前后表达水平的改变、细胞内的分布状况及其与分化和凋亡的关系。
结果：1)用100μM白藜芦醇处理细胞48h时后,对白藜芦醇敏感的髓母细胞瘤细胞系UW228-3细胞形态发生明显改变,而白藜芦醇并不能引起胶质母细胞瘤细胞系LN-18细胞形态的变化。2)在髓母细胞瘤细胞系UW228-3细胞中,白藜芦醇可以下调STAT3的表达水平并且使其核易位程度明显减少,而在胶质母细胞瘤细胞系LN-18细胞中,白藜芦醇可使STAT3发生核易位但对STAT3表达水平的影响很小。3)白藜芦醇可以明显上调髓母细胞瘤细胞系UW228-3细胞中LIF的表达水平,而对胶质母细胞瘤细胞系LN-18细胞中LIF表达水平的影响甚小。4)在髓母细胞瘤细胞系UW228-3细胞中,100μM白藜芦醇可不同程度地下调c-Myc、Survivin、Cox-2和CyclinD1的表达水平,上调Bcl-2的表达水平,而在胶质母细胞瘤细胞系LN-18细胞中100μM白藜芦醇对c-Myc、Survivin、Cox-2、CyclinD1和Bcl-2表达水平皆无明显影响。
结论：1)本研究证实100μtM白藜芦醇在诱导髓母细胞瘤细胞系UW228-3细胞发生分化和调亡的同时,抑制了STAT3通路的活化,而在胶质母细胞瘤细胞系LN-18细胞中白藜芦醇未呈现其抗肿瘤作用但是STAT3发生核易位。2)髓母细胞瘤细胞系UW228-3细胞对白藜芦醇的作用较敏感,而胶质母细胞瘤细胞系LN-18细胞对白藜芦醇的作用则具有耐药性。3)本研究进一步证实了对STAT3信号转导通路的抑制是白藜芦醇抗原发性脑肿瘤作用的重要分子机制。
Objective:To study the effect of STAT3 and its related factors LIF, c-Myc, Survivin, Cox-2, CyclinD1, Bcl-2 in resveratrol anti-medullo-blastoma cell line UW228-3 cells and anti-glioblastoma cell line LN-18 cells respectively, analyzing the relationship of STAT3 on cell growth, differentiation, apoptosis and drug resistance, investigating the molecular mechanism of resveratrol anti-medulloblastoma and anti-glioblastoma, so as to provide a new laboratory evidence and theoretic basis for improving the current clinical chemotherapy status of medulloblastoma and glioblastoma.
Methods:Human medulloblastoma cell line UW228-3 cells and glioblastoma cell line LN-18 cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium) culture medium containing 10% Fetal Bovine Serum (FBS). The cells (5×104/ml) were plated toΦ60mm andΦ100mm dishes and incubated for 24 hours before further experiments. Resveratrol was dissolved in dimethylsulfoxide to a stock concentration of 5mM and diluted with culture medium to an optimal working concentration of 100μM just before use. The cells were treated with resveratrol (100μM) for 48 hours, to observe the effect on the cells. Put sterilized cover slips in the dishes before cell seeding for cell morphology observation and immunocytochemistry (ICC) staining were performed. After above treatments, cover slips were collected and fixed with 100% cold acetone. Meanwhile, Cell suspension was collected and centrifuged to extract RNA and protein.Immunocyrochemistry (ICC) staining, RT-PCR Western blotting and other methods were used to analyze the expression levels and their intracellular distribution of STAT3 and its related factors LIF, c-Myc, Survivin, Cox-2, CyclinD1 and Bcl-2 in medulloblastoma cell line UW228-3 cells and glioblastoma cell line LN-18 cells with and without resveratrol treatment, in order to explore the expression levels, the distribution in intracellular and the correlation between STAT3 and its related factors LIF,c-Myc, Survivin, Cox-2, CyclinD1, Bcl-2 and differentiation, as well as apoptosis.
Results:1) On resveratrol-sensitive medulloblastoma line UW228-3 cells, the cell morphology changes apparent with resveratrol(100μM) treatment for 48 hours, but no obvious morphological changes were observed on glioblastoma cell line LN-18 cells with resveratrol (100μM) treatment for 48 hours.2) In the medulloblastoma cell line UW228-3 cells, resveratrol reduced the expression of STAT3 and its nuclear translocation levels decreased, whereas in glioblastoma cell line LN-18 cells, resveratrol can induce STAT3 nuclear translocation, but not much change on STAT3 expression levels.3) The expression of LIF significantly up-regulated in medulloblastoma cell line UW228-3 cells with resveratrol(100μM) treatment, whereas in glioblastoma cell line LN-18 cells, the expression of LIF did not change much.4) The expression of c-Myc, Survivin, Cox-2, CyclinD1 was down-regulated, Bcl-2 expression levels were significantly up-regulated in medulloblastoma cell line UW228-3 cells with resveratrol (100μM) treatment; c-Myc, Survivin, Cox-2, CyclinD1, Bcl-2 were no significant changes in expression levels in glioblastoma cell line LN-18 cells with and without resveratrol(100μM) treatment.
Conclusions:1) This study demonstrated that resveratrol(100μM) induced medulloblastoma cell line UW228-3 cells differentiation and apoptosis, while inhibited the STAT3 pathway activation; whereas in glioblastoma cell line LN-18 cells, resveratrol did not show its anti-tumor effect but the STAT3 nuclear translocation occured.2) The medulloblastoma cell line UW228-3 cells were sensitive to resveratrol, while the glioblastoma cell line LN-18 cells was resistant to resveratrol.3) The study further confirmed that the inhibition of STAT3 signaling pathway is an important anti-primary brain tumor molecular mechanism of resveratrol.
引文
1. Akira, S. et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway.Cell.1994; 77:63-71.
2. Zhong,Z.,Z. Wen,J.E.Darnell,Jr..Stat3:a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science.1994; 264:95-98.
3. Sara Pensa,Christine J. Watson, Valeria Poli. Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer. J Mammary Gland Biol Neoplasia.2009; 14:121-129.
4. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple
fronts. Cancer Metastasis Rev.2005; 24:315-327.
5. Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res.2007; 67:8494-8503.
6. C.P. Lim, X.Cao. Structure function and regulation of STAT proteins, Mol.Biosyst.2006; 2:536-550.
7. Zhiyong Ren, Xiang Mao, Claudia Mertens, Ravi Krishnaraj, Jie Qin, Pijus K. Mandal, Michael J. Romanowski, John S. McMurray, Xiaomin Chen. Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun.2008; 374:1-5.
8. Wenshan Hao, Yongbo Hu, Chuansheng Niu, Xinyi Huang, Chao-Pei Betty Chang, James Gibbons, Jun Xu. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett.2008; 18: 4988-4992.
9. X.Mao, Z. Ren, G.N. Parker, H. Sondermann, M.A. Pastorello, W. Wang, J.S.McMurray, B. Demeler, J.E.Darnell Jr., X. Chen, Structural bases of unphos-phorylated STAT1 association and receptor binding, Mol. Cell.2005; 17:761-771.
10. D. Neculai, A.M. Neculai, S. Verrier, K. Straub, K. Klumpp, E. Pfitzner, S. Becker. Structure of the unphosphorylated STAT5 a dimmer. J.Biol.Chem.2005; 280: 40782-40787.
11. C.Mertens, M.Zhong, R.Krishnaraj, W.Zou, X.Chen, et al. Dephosphorylation of phosphotyrosine on STAT1 dimmers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev.2006; 20:3372-3381.
12. M. Zhong, M.A. Henriksen, K. Takeuchi, O. Schaefer, B. Liu, J. ten Hoeve, Z. Ren, X. Mao, X. Chen, K.Shuai, et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle.Proc. Natl. Acad. Sci. USA.2005; 102:3966-3971.
13. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007; 13:5665-5669.
14.Feng Huang, Xiaoyun Tong, Liangqing Fu, and Ronghua Zhang. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin.2008; 40:519-525.
15. Jane L. Messina, Hua Yu, Adam I. Riker, Pamela N. Munster, Richard L. Jove, Adill. Daud. Activated Stat-3 in Melanoma. Cancer Control.2008; 15:196-201.
16. Charles E. Egwuagu. STAT3 in CD4+T helper cell differentiation and inflam-matory diseases. Cytokine.2009; 47:149-156
17. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets.2007; 7:91-107.
18.Nuria de la Iglesia, Genevieve Konopka, Sidharth V. Puram, Jennifer A. Chan, RobertM.Bachoo, Mingjian J. You, David E. Levy,Ronald A. DePinho,et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev.2008; 22:449-462.
19. Darnell J. E. Validating Stat3 in cancer therapy. Nat Med.2005; 11:595-596.
20. Paolo Cinelli, Elisa A Casanoval, Syndi Uhligl, Priska Lochmatter, Takahiko Matsuda, Takashi Yokota, Thomas Rulicke, Birgit Ledermann, et al. Expression profiling in transgenic FVB/N embryonic stem cells over expressing STAT3. BMC Dev Biol.2008; 8:1-17.
21. Andrea Canellada, Irene Alvarez, Luciana Berod, Teresa Gentile. Estrogen and progesterone regulate the IL-6 signal transduction pathway in antibody secreting cells. J Steroid Biochem Mol Biol.2008; 111:255-261.
22. Kristin Alberti, Ryan E Davey, Kento Onishi, Sophia George, Katrin Salchert, F Philipp Seib, Martin Bornha user, Tilo Pompe, Andras Nagy, et al. Functional immobilization of signaling proteins enables control of stem cell fate. Nat Methods.2008; 5:645-650.
23.Hiroshi Kida, Michael L. Mucenski, Angela R. Thitoff, Timothy D. Le Cras, Kwon-Sik Park, Machiko Ikegami, Werner Muller, Jeffrey A. Whitsett. GP130-STAT3 Regulates Epithelial Cell Migration and Is Required for Repair of the Bronchiolar Epithelium. Am J Pathol.2008; 172:1542-1554.
24. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway:clinical implications. Clin Cancer Res.2007; 13:1362-1366.
25. Kim DJ, Chan KS, Sano S, Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog.2007; 46:725-731.
26. Lilly Y. W. Bourguignonl, Karine Peyrollier, Weiliang Xia, and Eli Gilad.
Hyaluronan-CD44 Interaction Activates Stem Cell Marker, Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells. J Biol Chem.2008; 283:17635-17651.
27. Xie T., Huang F., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006; 66:3188-3196.
28. Joong-Won Lee, Hee-Jin Kwak, Je-Jung Lee, Yong-Nyun Kim, Jung Weon Lee,Myung-Jin Park, Seung Eun Jung, Seok-Il Hong, Jeong-Hwa Lee, Jae-Seon Lee. HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression. Eur J Cell Biol.2008; 87:377-387.
29. G. Frisullo, V. Nociti, R. Iorio, A. Katia Patanella, A. Bianco, M. Caggiula, C.Sancricca, P.A. Tonali, M. Mirabella, A.P. Batocchi, Glucocorticoid treatment reduces T-bet and pSTATl expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin. Immunol.2007; 124:284-293.
30. L.H. Wang, X.Y. Yang, X. Zhang, W.L. Farrar, Nuclear receptors as negative modulators of STAT3 in multiple myeloma, Cell Cycle.2005;4:242-245.
31. Kim H.S., Ye S.K., Cho I.H., Jung J. E., Kim D. H., Choi S., Kim Y. S., et al. 8-Hydroxydeoxy guanosine suppresses NO production and COX-2 activity via Racl/STATs signaling in LPS-induced brain microglia. Free Radic. Biol. Med.2006;41:1392-1403.
32. Hong Sook Kim, Ik Hyun Cho, Ja Eun Kim, Yong Jae Shin, Ju-Hong Jeon, Youngsoo Kim, Young Mok Yang, Kwang Ho Lee, Jung Weon Lee, Wang Jae Lee, Sang Kyu Ye, et al. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic Biol Med. 2008; 45:950-963.
33. Xuebin Liu, Yun Sang Lee, Cheng-Rong Yu, Charles E. Egwuagu. Loss of STAT3 in CD4+ T Cells Prevents Development of Experimental Autoimmune Diseases. J Immunol.2008; 180:6070-6076.
34. Harris, T. J., J. F. Grosso, H. R. Yen, H. Xin, M. Kortylewski, E. Albesiano, E. L. Hipkiss, D. Getnet, M. V. Goldberg, C. H. Maris, et al. Cutting edge:an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol.2007;179:4313-4317.
35. M. K. Kang,S. K. Kang. Interleukin-6 induces proliferation in adult spinal cord-derived neural progenitors via the JAK2/STAT3 pathway with EGF-induced MAPK phosphorylation. Cell Prolif.2008; 41:377-392.
36. Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M. JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem.2008; 107:50-60.
37. Yamauchi K., Osuka K., Takayasu M., Usuda N., Nakazawa A., Nakahara N., Yoshida M., Aoshima C., Hara M. and Yoshida J. Activation of JAK/STAT signalling in neurons following spinal cord injury in mice. J. Neurochem.2006; 96:1060-1070.
38. Sanz E., Hofer M. J., Unzeta M. and Campbell I. L. Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain. Glia.2008; 56:190-199.
39. Christoph Buettner, Evan D Muse, Andrew Cheng, Linghong Chen, Thomas Scherer,Alessandro Pocai, Kai Su, Bob Cheng, Xiasong Li, Judith Harvey-White, Gary J Schwartz,George Kunos,et al. Leptincontrols adipose tissue lipogenesis via central,STAT3-independent mechanisms. Nat Med.2008; 14:667-675.
40. Andrea Frontini, Paola Bertolotti, Cristina Tonello, Alessandra Valerio,Enzo Nisoli, Saverio Cinti, Antonio Giordano. Leptin-dependent STAT3 phos-phorylation in postnatal mouse hypothalamus. Brain Res.2008; 1215:105-115.
41.Xinxin Yu, Byung-Hyun Park, May-Yun Wang, Zhao V. Wang, and Roger H. Unger. Making insulin-deficient type 1 diabetic rodents thrive without insulin. PNAS.2008;105:14070-14075.
42. Nefedova Y, Gabrilovich DI. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets.2007; 7:71-77.
43. Guido A.M. Tiberio, Laura Tiberio, Anna Benetti, Edoardo Cervi, Nadia Montani, Michel Dreano,Gianni Garotta, Katia Cerea, Nathalie Steimberg, GianPietro Pandolfo, Andrea Ferrari-Bravo, Giovanna Mazzoleni, Stefano M. Giulini, Luisa Schiaffonati.IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy. Cytokine.2008; 42:372-378.
44. Matsuzaki Y, Xu Y, Ikegami M, Besnard V, Park KS, Hull WM, Wert SE, Whitsett JA:Stat3 is required for cytoprotection of the respiratory epithelium during adenoviral infection. J Immunol 2006; 177:527-537.
45. Kida H, Yoshida M, Hoshino S, Inoue K, Yano Y, Yanagita M, Kumagai T, Osaki T, Tachibana I, Saeki Y, Kawase I. Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J. Physiol.2005; 288:342-349.
46. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol.2007; 27: 4444-4453.
47. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X.Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol.2006; 172:245-257.
48. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE.2006; 343:pe30.
1. Soledad Miranda, Agueda Gonzalez-Rodriguez,et al.Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro-and anti-inflammatory stimuli. Cell Signal.2010; 22:645-659
2. J.Zhu,W.Yong,X.Wu,Y.Yu,J.Lv,C.Liu,X. Mao, Y. Zhu, K. Xu,X. Han,C. Liu Anti-inflammatory effect of resveratrol on TNF-α-induced MCP-1 expression in adipocytes.Biochem. Biophys. Res. Commun.2008; 369:471-477.
3. M. Emilia Juan, Eulalia Gonza'lez-Pons, Joana M. Planas. Multidrug Resistance Proteins Restrain the Intestinal Absorption of trans-Resveratrol in Rats. J. Nutr. 2010; 140:489-495.
4. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction:to die or not to die. Mol Nutr Food Res.2009; 53:115-128.
5. Huige Li,Ulrich Forstermann. Resveratrol:A Multifunctional Compound Improving Endothelial Function. Cardiovasc Drugs Ther.2009; 23:425-429.
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol:the in vivo evidence. Nat Rev Drug Discov.2006; 5:493-506.
7. Opie LH, Lecour S. The red wine hypothesis:from concepts to protective signaling molecules. Eur Heart J.2007; 28:1683-1693.
8. Murugan Sengottuvelan, Kumaraswamy Deeptha, M. Phil., Namasivayam Nalini. Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition.2009; 25:1169-1176.
9. Jayne Abraham, Rodney W. Johnson. Consuming a Diet Supplemented with Resveratrol Reduced Infection-Related Neuroinflammation and Deficits in Working Memory in Aged Mice. Rejuvenation Res.2009; 12:445-453.
10. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature.2006; 444: 337-342.
11. Athar M, Back JH, Tang X, Kim KH, Kopelovich L,Bickers DR,Kim AL Resveratrol:A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol.2007;224:274-283.
12. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol:molecular mechanisms and therapeutic potential. Front Biosci.2007; 12:4839-4854.
13. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets.2007; 6:168-173.
14. Ruweler M, Gulden M, Maser E, Murias M,Seibert H.Cytotoxic,cytoprotective and antioxidant activities of resveratrol and analogues in C6 astroglioma cells in vitro. Chem Biol Interact.2009; 182:128-135.
15. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. Cancer chemo-preventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275:218-220.
16. Shi WF, Leong M, Cho E, Farrell J, Chen HC, Tian J, Zhang D. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One. 2009; 4:e7398
17. Kim MY, Trudel LJ, Wogan GN. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res.2009; 29:3733-3740.
18. Liu BQ, Gao YY, Niu XF, Xie JS, Meng X, Guan Y, Wang HQ. Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. Biochem Biophys Res Commun.2010; 391:778-782.
19. Shinwari Zakia, Manogaran Pulicat S.I, Alrokayan Salman A., et al. Vincristine and lomustine induce apoptosis and p21WAF1 up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. J Neurooncol.2008; 87:123-132.
20. Fabio E. da Silva,Ana B. Cordeiro,Cleusa Y. Nagamachi,Julio C. Pieczarka, Willen Rens,Anja Weise,Thomas Liehr,Hasmik Mkrtchyan, Nilson P. Anselmo, Edivaldo H.C. de Oliveira. A case of aggressive medulloblastoma with multiple recurrent chromosomal alterations. Cancer Genet Cytogenet.2010; 196:198-200.
21. Martin Gerard McCabe, Koichi Ichimura, et al.High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal Tumors. J Neuropathol Exp Neurol.2006; 65:549-561.
22. Rajeev Vibhakar, Beverly L. Davidson, Anup Madan.Adenoviral Mediated Re-Expression of Wnt Antagonist Dkk-1 Induces Apoptosis and Suppresses Tumor Growth in Medulloblastoma. Mol Ther.2006; 13:s363.
23. Yuan Lu, Sarra L. Ryan, David J. Elliott, Graham R. Bignell, P. Andrew Futreal, David W. Ellison,Simon Bailey, Steven C. Clifford. Amplification and Over-expression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in Medulloblastoma. PLoS ONE.2009; 4:e6159.
24. Pizer B, Clifford S.Medulloblastoma:new insights into biology and treatment. Arch Dis Child Educ Pract Ed.2008; 93:137-144.
25. Liang Yu,Diehn Maximilian, Bollen Andrew W.,Israel Mark A.,Gupta Nalin. Type Ⅰ collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. J Neurooncol.2008; 86:133-141.
26. Patrick Y.Wen, Santosh Kesari.Malignant Gliomas in Adults.N Engl J Med.2008; 359:492-507.
27. Huan J. Chang, Alison E. Burke, Richard M. Glass. Gliomas. JAMA.2010; 303:1000.
28. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, Holland EC.Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell.2010;6: 141-152.
29. Roel G.W. Verhaak,Katherine A. Hoadley，Elizabeth Purdom,Victoria Wang,Yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd Golub,Jill P. Mesirov, Gabriele Alexe,Michael Lawrence,et al.The Cancer Genome Atlas Research Network. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell.2010; 17:98-110.
30. Heiko Wurdak,Shoutian Zhu,Angelica Romero,Mihaela Lorger,James Watson, Chih-yuan Chiang,Jay Zhang,VanitaS.Natu,Luke L. Lairson,John R. Walker, Christopher M. Trussell,Griffith R. Harsh,Hannes Vogel,Brunhilde Felding-Habermann,Anthony P. Orth,Loren J. Miraglia,Daniel R. Rines,et al.An RNAi Screen Identifies TRRAP as a Regulator of Brain Tumor-Initiating Cell Differen-tiation. Cell Stem Cell.2010; 6:37-47.
31. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival:an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol.2008; 10:162-170.
32. Marc C. Chamberlain.10 questions about the use of bevacizumab in the manage-ment of recurrent malignant gliomas. The Neurologist.2010; 16:56-60.
33. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL,Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours.Nature. 2010; 463:318-325.
34. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A.,Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.2007; 21:2683-2710.
35. Jakub Godlewski，Michal O. Nowicki,Agnieszka Bronisz,Gerard Nuovo,Jeff Palatini,Michael De Lay,JamesVanBrocklyn,Michael C. Ostrowski,E. Antonio Chiocca, Sean E. Lawler. MicroRNA-451 Regulates LKB1/AMPK Signaling and Allows Adaptation to Metabolic Stress in Glioma Cells. Mol Cell.2010; 37:620-632.
36. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol.2007; 170:1445-1453.
37. Yoji Yamashita,Isao Kasugai,Masami Sato,Nobuhiro Tanuma,Ikuro Sato,Miyuki Nomura,Katsumi Yamashita,Yukihiko Sonoda,Toshihiro Kumabe, et al. CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples. J Neurooncol.2010; online.
38. Sathornssumetee S,Reardon DA,Desjardins A,Quinn JA,Vredenburgh JJ,et al. Molecularly targeted therapy for malignant glioma.Cancer.2007; 110:13-24.
39. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P,Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R,Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA,Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL,Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science.2008; 321:1807-1812.
40. Saad Z. Usmani, Robert Bona,Zihai Li.17 AAG for HSP90 Inhibition in Cancer-From Bench to Bedside. Curr Mol Med.2009; 9:654-664
41. Clark JC, Dass CR, Choong PF.Development of chondrosarcoma animal models for assessment of adjuvant therapy. ANZ J Surg.2009; 79:327-336.
42. Sui Xiong Cai, John Drewe,William Kemnitzer.Discovery of 4-Aryl-4H-Chromenes as Potent Apoptosis Inducers Using a Cell-and Caspase-Based Anti-Cancer Screening Apoptosis Program (ASAP):SAR Studies and the Identification of Novel Vascular Disrupting Agents. Anticancer Agents Med Chem.2009; 9:437-456.
43. Christophe Le Tourneau, J. Jack Lee, Lillian L. Siu. Dose Escalation Methods in Phase Ⅰ Cancer Clinical Trials. J Natl Cancer Inst.2009; 101:708-720.
44. Alfonso Quinta's-Cardama, Hagop Kantarjian, Jorge Cortes. Homoharringtonine, Omacetaxine Mepesuccinate, and Chronic Myeloid Leukemia Circa. Cancer.2009; 115:5382-5393.
45. Sandra E. Ghayad,Pascale A. Cohen. Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients. Recent Pat Anticancer Drug Discov.2010; 5:29-57.
46. Q.-B. Han, H.-X. Xu. Caged Garcinia Xanthones:Development Since 1937. Curr Med Chem..2009; 16:3775-3796.
47. Ken-Ichi Shinohara, Toshikazu Bando,Hiroshi Sugiyama. Anticancer activities of alkylating pyrrole-imidazole polyamides with specific sequence recognition. Anti-Cancer Drugs.2010; 21:228-242
48. Xianghui Ma, Zhiwen Wang. Anticancer drug discovery in the future:an evolutionary perspective. Drug Discov Today.2009; 14:1136-1142.
49. Sabine H. van Rijt, Peter J. Sadler. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today.2009; 14:1089-1097.
50. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell.1994; 77:63-71.
51. Sara Pensa,Christine J. Watson, Valeria Poli. Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer. J Mammary Gland Biol Neoplasia.2009; 14:121-129.
52. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature.2007; 448:1058-1062.
53. Sizhi Paul Gao, Kevin G. Mark, Kenneth Leslie, William Pao, Noriko Motoi, William L. Gerald, William D. Travis, William Bornmann, Darren Veach, Bayard Clarkson,Jacqueline F. Bromberg. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest.2007; 117:3846-3856.
54. Daniel J. Gough,Alicia Corlett,Karni Schlessinger,Joanna Wegrzyn, et al. Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation. Science.2009; 324:1713-1716.
55. Huaqi Jiang,Parthive H. Patel,Alexander Kohlmaier,Marc O. Grenley,Donald G. McEwen,and Bruce A. Edgar. Cytokine/Jak/Stat Signaling Mediates Regene-ration and Homeostasis in the Drosophila Midgut. Cell.2009; 137:1343-1355.
56. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007; 7:91-107.
57. Feng Huang, Xiaoyun Tong, Liangqing Fu, and Ronghua Zhang. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin.2008; 40:519-525.
58. Yu H., Kortylewski M, Pardoll D.. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev. Immunol.2007; 7, 41-51.
59. Marcin Kortylewski and Hua Yu. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol.2008; 20:228-233.
60. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature.2008; 454:436-44.
61. Joanna Wegrzyn,Ramesh Potla,Yong-Joon Chwae.Naresh B.V.Sepuri,Qifang Zhang,et al. Function of Mitochondrial Stat3 in Cellular Respiration. Science. 2009; 323:793-797.
62. Paolo Cinelli, Elisa A Casanoval, Syndi Uhligl, Priska Lochmatter,Takahiko Matsuda, Takashi Yokota, Thomas Riilicke, Birgit Ledermann, and Kurt Burki. Expression profiling in transgenic FVB/N embryonic stem cells overexpressing STAT3. BMC Dev Biol.2008; 8:1-17.
63. Marina Cella, Anja Fuchs, William Vermi, Fabio Facchetti, Karel Otero, Jochen K. M. Lennerz,Jason M. Doherty, Jason C. Mills,Marco Colonna. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity.Nature.2009; 457:722-725.
64. Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature.2007; 445:648-651.
65. Dae-Seop Shin,Hye-Nan Kim,Ki Deok Shin,Young Ju Yoon,Seung-Jun Kim,Dong Cho Han,Byoung-Mog Kwon.Cryptotanshinone Inhibits Constitutive Signal
Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells. Cancer Res.2009; 69:193-202.
66. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:a leading role for STAT3. Nat Rev Cancer.2009; 9:798-809.
67. Lilly Y. W. Bourguignonl, Karine Peyrollier, Weiliang Xia, and Eli Gilad. Hyaluronan-CD44 Interaction Activates Stem Cell Marker, Nanog. Stat-3-mediated MDR1 Gene Expression and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells. J Biol Chem.2008; 283:17635-17651.
68. Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, prolife-ration, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res.2009; 7:118-128.
69. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM.Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res.2009; 69:193-202.
70. Newman DJ. Natural products as leads to potential drugs:an old process or the new hope for drug discovery? J Med Chem.2008; 51:2589-2599.
71. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR. Establishment and characterization of four human medulloblastoma-derived cell lines.Oncol Res.1995;7:493-503.
72. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia.2005; 7:967-976.
73. Jung EM, Lee TJ, Park JW, Bae YS, Kim SH, Choi YH, Kwon TK.The novel phospholipase C activator, m-3M3FBS,induces apoptosis in tumor cells through caspase activation, down-regulation of XIAP and intracellular calcium signaling. Apoptosis 2008; 13:133-145.
74. Ben-Shlomo A, Miklovsky I, Ren SG, Yong WH, Heaney AP, Culler MD, Melmed S. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. J Clin Endocrinol Metab.2003; 88:858-863.
75. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN,Rorke LB, Brodeur GM, Phillips PC. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.Clin Cancer Res 2001; 7:2425-2433.
76. Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA,Kumar AP. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer:potential role for nexrutine. Neoplasia.2007; 9:893-899.
77. Simile MM, De Miglio MR, Muroni MR, Frau M, Asara G, Serra S, Muntoni MD, Seddaiu MA, Daino L, Feo F, et al. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis.2004; 25:333-341.
78. Li-Jun Yu, Mo-Li Wu, Hong Li, Xiao-Yan Chen,Qian Wang, Yuan Sun, Qing-You Kong,Jia Liu. Inhibition of STAT3 Expression and Signaling in Resveratrol-Differentiated Medulloblastoma Cells. Neoplasia.2008; 10:736-744.
79. Jeong-Yeh Yang, Mary Anne Della-Fera, Srujana Rayalam, Suresh Ambati, Diane L. Hartzell, Hea Jin Park,Clifton A. Baile. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci.2008; 82:1032-1039.
80. Hao Jiangl, Xia Shang, Hongtao Wu, Subhash C. Gautam, Shaza Al-Holou, Christina Li, Jarret Kuo, Lijie Zhang, and Michae Chopp. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol.2009; 8:25-33.
81. J.K. Kundu, Y.J. Surh, Cancer chemopreventive and therapeutic potential of resveratrol:mechanistic perspectives.Cancer Lett.2008; 269:243-261.
82. Hichem Sebai, Elodie Ristorcelli, Veronique Sbarra, Sonia Hovsepian, Guy Fayet, Ezzedine Aouani,Dominique Lombardo. Protective effect of resveratrol against LPS-induced extracellular lipoperoxidation in AR42J cells partly via a Myd88-dependent signaling pathway. Arch Biochem Biophys.2010; 495:56-61.
83. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate.2007; 67:1641-1653.
84. Hsieh TC.Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells. Asian J Androl.2009; 11:653-661.
85. Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S,Potter BV, Broggini M, Maffucci T. A novel inhibitor of the PI3K/Akt pathway based on
the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer.2010; 102:104-114.
86. Elisabeth M. Perchellet, Jean-Pierre H. Perchellet, Chanran K. Ganta, Deryl L. Troyer, Aibin Shi,Duy H. Hua. Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1-Oxopyrano[4,3-b] Benzopyrans and Nanogels for Drug Delivery. Anticancer Agents Med Chem.2009;9:864-876.
87. Christophe Rochais, Patrick Dallemagne, Sylvain Rault. Tripentones:A Promising Series of Potent Anti-Cancer Agents. Anticancer Agents Med Chem. 2009;9:369-380.
88. Arkenau HT. Gastric cancer in the era of molecularly targeted agents:current drug development strategies. J Cancer Res Clin Oncol.2009; 135:855-866.
89. D.J.Gough, A.Corlett, K Schlessinger, J.Wegrzyn, A.C.Larner,D.E.Levy. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009; 324:1713-1716.
90. S J Baker, S G Rane, E P Reddy. Hematopoietic cytokine receptor signaling. Oncogene.2007; 26:6724-6737.
91. Grivennikov S., Karin M. Autocrine IL-6 signaling:a key event in tumourigenesis? Cancer Cell.2008; 13:7-9.
92. Sandra Rebouissou, Mohamed Amessou, Gabrielle Couchy, Karine Poussin, Sandrine Imbeaud,Camilla Pilati, Tina Izard, Charles Balabaud,et al.Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.Nature.2009; 457:200-205.
93. Rigby R.J.,Simmons J.G.,Greenhalgh C.J.,et al.Suppressor of cytokine signaling 3(SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in thecolon. Oncogene.2007; 26:4833-4841.
94. Ping Li,Chang Tong,Ruty Mehrian-Shai,Li Jia,Nancy Wu,Youzhen Yan,Robert E. Maxson,Eric N. Schulze,HouyanSong,Chih-Lin Hsieh,Martin F. Pera,Qi-Long Ying. Germline Competent Embryonic Stem Cells Derived from Rat Blastocysts. Cell.2008; 135:1299-1310.
95. Ryan Conderl and Juergen A. Knoblichl. Fly stem cell Research Gets Infectious. Cell.2009; 137:1185-1187.
96. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S,Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood.2007; 109:2293-2302.
97. Lu X.,Chen J., Sasmono R.T., His E.D., Sarosiek K.A., et al.T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol.Cell. Biol.2007; 27:2166-2179.
98. Ben J. Shields, Christine Hauser,Patricia E. Bukczynska, Naomi W. Court,and Tony Tiganis. DNA Replication Stalling Attenuates TyrosineKinase Signaling to Suppress S Phase Progression. Cancer Cell.2008; 14:166-179.
99. Li J, Piao YF, Jiang Z, Chen L, Sun HB. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J Gas-troenterol.2009; 15:2602-2608.
100. Torres L, Sandoval J, Penella E, Zaragoza R, Garcia C, Rodriguez JL, Vina JR, Garcia-Trevijano ER. In vivo GSH depletion induces c-myc expression by modulation of chromatin protein complexes. Free Radic Biol Med.2009; 46: 1534-1542.
101. Jinhai Gu,Gang Li,Tao Sun,Yuhang Su,Xulong Zhang, Jie Shen, Zhigang Tian, Jian Zhang. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant gliomacells. J Neurooncol.2008; 89:9-17.
102. Qiu Z,Huang C,Sun J,Qiu W,Zhang J,Li H,Jiang T,Huang K,Cao J. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci.2007; 98:1099-1106.
103. Sandrine Ruchaud, Mar Carmena, William C. Earnshaw. The Chromosomal Passenger Complex:One for All and All for One. Cell.2007;131:230-231.
104. Christian Pohl, Stefan Jentsch. Final Stages of Cytokinesis and Midbody Ring Formation Are Controlled by BRUCE. Cell.2008; 132:832-845.
105. Sergei I. Grivennikov,Florian R. Greten,Michael Karin. Immunity, Inflammation, and Cancer. Cell.2010; 140:883-899.
106. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res.2008; 314:1163-1176.
107. Da Costa SV, Roela RA, Junqueira MS, Arantes C, Brentani MM. The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes. Leuk Res.2010;34:507-12.
108. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al.. Thelandscape of somatic copy-number alteration across human cancers. Nature.2010; 463: 899-905.
109. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA. c-Myc regulates transcriptional pause release. Cell.2010; 141:432-445.
110. Dai CH, Li J, Shi SB, Yu LC, Ge LP, Chen P. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol.2010; 40:327-335.
111. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, Papadaki H. Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol.2010; 25:299-307.
112. Liu XA, Liao K, Liu R, Wang HH, Zhang Y, Zhang Q, Wang Q, et al. Tau dephosphorylation potentiates apoptosis by mechanisms involving a failed dephosphorylation/activation of Bcl-2. J Alzheimers Dis.2010; 19:953-962.
113.Absalan F, Movahedin M, Mowla SJ. Germ cell apoptosis induced by experimental cryptorchidism is mediated by molecular pathways in mouse testis. Andrologia.2010;42:5-12.
114. Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int.2007; 7:4.
115. Ge KL, Chen WF, Xie JX, Wong MS. Ginsenoside Rgl protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways. J Ethnopharmacol.2010; 127:118-123.
116. Jie Yang, Xuesong Liu, Kapil Bhalla, Caryn Naekyung Kim, Ana Maria Ibrado, Jiyang Cai, Tsung-I Peng, Dean P. Jones, Xiaodong Wang. Prevention of Apoptosis by Bcl-2:Release of Cytochrome c from Mitochondria Blocked. Science.1997; 275:1129-1132.
117. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foa R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia.2009; 11:720-731.
118. Jie Yang, Xuesong Liu, Kapil Bhalla, Caryn Naekyung Kim, Ana Maria Ibrado, Jiyang Cai, Tsung-Ⅰ Peng, Dean P. Jones, Xiaodong Wang. Prevention of Apoptosis by Bcl-2:Release of Cytochrome c from Mitochondria Blocked. Science.1997; 275:1129-1132.
119. Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, Jeong HG. Bisphenol A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol Lett.2010; 193:200-208.
120. Rosa Sirianni, Adele Chimento, Arianna De Luca, Fabiana Zolea, Amalia Carpino, Vittoria Rago, Marcello Maggiolini, et al. Inhibition of Cyclo-oxygenase-2 Down-regulates Aromatase Activity and Decreases Proliferation of Leydig Tumor Cells. J Biol Chem.2009; 284:28905-28916.
121. Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvⅢ-STAT3 signaling axes. Cancer Res.2010; 8:232-245.
122.Kwak HJ, Park KM, Choi HE, Park HY. Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells:role of PKC and COX-2. Free Radic Res.2009;43:744-752.
2. Zhong,Z.,Z. Wen,J.E.Darnell,Jr..Stat3:a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science.1994; 264:95-98.
3. Sara Pensa,Christine J. Watson, Valeria Poli. Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer. J Mammary Gland Biol Neoplasia.2009; 14:121-129.
4. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple
fronts. Cancer Metastasis Rev.2005; 24:315-327.
5. Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res.2007; 67:8494-8503.
6. C.P. Lim, X.Cao. Structure function and regulation of STAT proteins, Mol.Biosyst.2006; 2:536-550.
7. Zhiyong Ren, Xiang Mao, Claudia Mertens, Ravi Krishnaraj, Jie Qin, Pijus K. Mandal, Michael J. Romanowski, John S. McMurray, Xiaomin Chen. Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun.2008; 374:1-5.
8. Wenshan Hao, Yongbo Hu, Chuansheng Niu, Xinyi Huang, Chao-Pei Betty Chang, James Gibbons, Jun Xu. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett.2008; 18: 4988-4992.
9. X.Mao, Z. Ren, G.N. Parker, H. Sondermann, M.A. Pastorello, W. Wang, J.S.McMurray, B. Demeler, J.E.Darnell Jr., X. Chen, Structural bases of unphos-phorylated STAT1 association and receptor binding, Mol. Cell.2005; 17:761-771.
10. D. Neculai, A.M. Neculai, S. Verrier, K. Straub, K. Klumpp, E. Pfitzner, S. Becker. Structure of the unphosphorylated STAT5 a dimmer. J.Biol.Chem.2005; 280: 40782-40787.
11. C.Mertens, M.Zhong, R.Krishnaraj, W.Zou, X.Chen, et al. Dephosphorylation of phosphotyrosine on STAT1 dimmers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev.2006; 20:3372-3381.
12. M. Zhong, M.A. Henriksen, K. Takeuchi, O. Schaefer, B. Liu, J. ten Hoeve, Z. Ren, X. Mao, X. Chen, K.Shuai, et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle.Proc. Natl. Acad. Sci. USA.2005; 102:3966-3971.
13. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007; 13:5665-5669.
14.Feng Huang, Xiaoyun Tong, Liangqing Fu, and Ronghua Zhang. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin.2008; 40:519-525.
15. Jane L. Messina, Hua Yu, Adam I. Riker, Pamela N. Munster, Richard L. Jove, Adill. Daud. Activated Stat-3 in Melanoma. Cancer Control.2008; 15:196-201.
16. Charles E. Egwuagu. STAT3 in CD4+T helper cell differentiation and inflam-matory diseases. Cytokine.2009; 47:149-156
17. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets.2007; 7:91-107.
18.Nuria de la Iglesia, Genevieve Konopka, Sidharth V. Puram, Jennifer A. Chan, RobertM.Bachoo, Mingjian J. You, David E. Levy,Ronald A. DePinho,et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev.2008; 22:449-462.
19. Darnell J. E. Validating Stat3 in cancer therapy. Nat Med.2005; 11:595-596.
20. Paolo Cinelli, Elisa A Casanoval, Syndi Uhligl, Priska Lochmatter, Takahiko Matsuda, Takashi Yokota, Thomas Rulicke, Birgit Ledermann, et al. Expression profiling in transgenic FVB/N embryonic stem cells over expressing STAT3. BMC Dev Biol.2008; 8:1-17.
21. Andrea Canellada, Irene Alvarez, Luciana Berod, Teresa Gentile. Estrogen and progesterone regulate the IL-6 signal transduction pathway in antibody secreting cells. J Steroid Biochem Mol Biol.2008; 111:255-261.
22. Kristin Alberti, Ryan E Davey, Kento Onishi, Sophia George, Katrin Salchert, F Philipp Seib, Martin Bornha user, Tilo Pompe, Andras Nagy, et al. Functional immobilization of signaling proteins enables control of stem cell fate. Nat Methods.2008; 5:645-650.
23.Hiroshi Kida, Michael L. Mucenski, Angela R. Thitoff, Timothy D. Le Cras, Kwon-Sik Park, Machiko Ikegami, Werner Muller, Jeffrey A. Whitsett. GP130-STAT3 Regulates Epithelial Cell Migration and Is Required for Repair of the Bronchiolar Epithelium. Am J Pathol.2008; 172:1542-1554.
24. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway:clinical implications. Clin Cancer Res.2007; 13:1362-1366.
25. Kim DJ, Chan KS, Sano S, Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog.2007; 46:725-731.
26. Lilly Y. W. Bourguignonl, Karine Peyrollier, Weiliang Xia, and Eli Gilad.
Hyaluronan-CD44 Interaction Activates Stem Cell Marker, Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells. J Biol Chem.2008; 283:17635-17651.
27. Xie T., Huang F., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006; 66:3188-3196.
28. Joong-Won Lee, Hee-Jin Kwak, Je-Jung Lee, Yong-Nyun Kim, Jung Weon Lee,Myung-Jin Park, Seung Eun Jung, Seok-Il Hong, Jeong-Hwa Lee, Jae-Seon Lee. HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression. Eur J Cell Biol.2008; 87:377-387.
29. G. Frisullo, V. Nociti, R. Iorio, A. Katia Patanella, A. Bianco, M. Caggiula, C.Sancricca, P.A. Tonali, M. Mirabella, A.P. Batocchi, Glucocorticoid treatment reduces T-bet and pSTATl expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin. Immunol.2007; 124:284-293.
30. L.H. Wang, X.Y. Yang, X. Zhang, W.L. Farrar, Nuclear receptors as negative modulators of STAT3 in multiple myeloma, Cell Cycle.2005;4:242-245.
31. Kim H.S., Ye S.K., Cho I.H., Jung J. E., Kim D. H., Choi S., Kim Y. S., et al. 8-Hydroxydeoxy guanosine suppresses NO production and COX-2 activity via Racl/STATs signaling in LPS-induced brain microglia. Free Radic. Biol. Med.2006;41:1392-1403.
32. Hong Sook Kim, Ik Hyun Cho, Ja Eun Kim, Yong Jae Shin, Ju-Hong Jeon, Youngsoo Kim, Young Mok Yang, Kwang Ho Lee, Jung Weon Lee, Wang Jae Lee, Sang Kyu Ye, et al. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic Biol Med. 2008; 45:950-963.
33. Xuebin Liu, Yun Sang Lee, Cheng-Rong Yu, Charles E. Egwuagu. Loss of STAT3 in CD4+ T Cells Prevents Development of Experimental Autoimmune Diseases. J Immunol.2008; 180:6070-6076.
34. Harris, T. J., J. F. Grosso, H. R. Yen, H. Xin, M. Kortylewski, E. Albesiano, E. L. Hipkiss, D. Getnet, M. V. Goldberg, C. H. Maris, et al. Cutting edge:an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol.2007;179:4313-4317.
35. M. K. Kang,S. K. Kang. Interleukin-6 induces proliferation in adult spinal cord-derived neural progenitors via the JAK2/STAT3 pathway with EGF-induced MAPK phosphorylation. Cell Prolif.2008; 41:377-392.
36. Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M. JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem.2008; 107:50-60.
37. Yamauchi K., Osuka K., Takayasu M., Usuda N., Nakazawa A., Nakahara N., Yoshida M., Aoshima C., Hara M. and Yoshida J. Activation of JAK/STAT signalling in neurons following spinal cord injury in mice. J. Neurochem.2006; 96:1060-1070.
38. Sanz E., Hofer M. J., Unzeta M. and Campbell I. L. Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain. Glia.2008; 56:190-199.
39. Christoph Buettner, Evan D Muse, Andrew Cheng, Linghong Chen, Thomas Scherer,Alessandro Pocai, Kai Su, Bob Cheng, Xiasong Li, Judith Harvey-White, Gary J Schwartz,George Kunos,et al. Leptincontrols adipose tissue lipogenesis via central,STAT3-independent mechanisms. Nat Med.2008; 14:667-675.
40. Andrea Frontini, Paola Bertolotti, Cristina Tonello, Alessandra Valerio,Enzo Nisoli, Saverio Cinti, Antonio Giordano. Leptin-dependent STAT3 phos-phorylation in postnatal mouse hypothalamus. Brain Res.2008; 1215:105-115.
41.Xinxin Yu, Byung-Hyun Park, May-Yun Wang, Zhao V. Wang, and Roger H. Unger. Making insulin-deficient type 1 diabetic rodents thrive without insulin. PNAS.2008;105:14070-14075.
42. Nefedova Y, Gabrilovich DI. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets.2007; 7:71-77.
43. Guido A.M. Tiberio, Laura Tiberio, Anna Benetti, Edoardo Cervi, Nadia Montani, Michel Dreano,Gianni Garotta, Katia Cerea, Nathalie Steimberg, GianPietro Pandolfo, Andrea Ferrari-Bravo, Giovanna Mazzoleni, Stefano M. Giulini, Luisa Schiaffonati.IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy. Cytokine.2008; 42:372-378.
44. Matsuzaki Y, Xu Y, Ikegami M, Besnard V, Park KS, Hull WM, Wert SE, Whitsett JA:Stat3 is required for cytoprotection of the respiratory epithelium during adenoviral infection. J Immunol 2006; 177:527-537.
45. Kida H, Yoshida M, Hoshino S, Inoue K, Yano Y, Yanagita M, Kumagai T, Osaki T, Tachibana I, Saeki Y, Kawase I. Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J. Physiol.2005; 288:342-349.
46. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol.2007; 27: 4444-4453.
47. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X.Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol.2006; 172:245-257.
48. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE.2006; 343:pe30.
1. Soledad Miranda, Agueda Gonzalez-Rodriguez,et al.Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro-and anti-inflammatory stimuli. Cell Signal.2010; 22:645-659
2. J.Zhu,W.Yong,X.Wu,Y.Yu,J.Lv,C.Liu,X. Mao, Y. Zhu, K. Xu,X. Han,C. Liu Anti-inflammatory effect of resveratrol on TNF-α-induced MCP-1 expression in adipocytes.Biochem. Biophys. Res. Commun.2008; 369:471-477.
3. M. Emilia Juan, Eulalia Gonza'lez-Pons, Joana M. Planas. Multidrug Resistance Proteins Restrain the Intestinal Absorption of trans-Resveratrol in Rats. J. Nutr. 2010; 140:489-495.
4. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction:to die or not to die. Mol Nutr Food Res.2009; 53:115-128.
5. Huige Li,Ulrich Forstermann. Resveratrol:A Multifunctional Compound Improving Endothelial Function. Cardiovasc Drugs Ther.2009; 23:425-429.
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol:the in vivo evidence. Nat Rev Drug Discov.2006; 5:493-506.
7. Opie LH, Lecour S. The red wine hypothesis:from concepts to protective signaling molecules. Eur Heart J.2007; 28:1683-1693.
8. Murugan Sengottuvelan, Kumaraswamy Deeptha, M. Phil., Namasivayam Nalini. Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition.2009; 25:1169-1176.
9. Jayne Abraham, Rodney W. Johnson. Consuming a Diet Supplemented with Resveratrol Reduced Infection-Related Neuroinflammation and Deficits in Working Memory in Aged Mice. Rejuvenation Res.2009; 12:445-453.
10. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature.2006; 444: 337-342.
11. Athar M, Back JH, Tang X, Kim KH, Kopelovich L,Bickers DR,Kim AL Resveratrol:A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol.2007;224:274-283.
12. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol:molecular mechanisms and therapeutic potential. Front Biosci.2007; 12:4839-4854.
13. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets.2007; 6:168-173.
14. Ruweler M, Gulden M, Maser E, Murias M,Seibert H.Cytotoxic,cytoprotective and antioxidant activities of resveratrol and analogues in C6 astroglioma cells in vitro. Chem Biol Interact.2009; 182:128-135.
15. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. Cancer chemo-preventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275:218-220.
16. Shi WF, Leong M, Cho E, Farrell J, Chen HC, Tian J, Zhang D. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One. 2009; 4:e7398
17. Kim MY, Trudel LJ, Wogan GN. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res.2009; 29:3733-3740.
18. Liu BQ, Gao YY, Niu XF, Xie JS, Meng X, Guan Y, Wang HQ. Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. Biochem Biophys Res Commun.2010; 391:778-782.
19. Shinwari Zakia, Manogaran Pulicat S.I, Alrokayan Salman A., et al. Vincristine and lomustine induce apoptosis and p21WAF1 up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. J Neurooncol.2008; 87:123-132.
20. Fabio E. da Silva,Ana B. Cordeiro,Cleusa Y. Nagamachi,Julio C. Pieczarka, Willen Rens,Anja Weise,Thomas Liehr,Hasmik Mkrtchyan, Nilson P. Anselmo, Edivaldo H.C. de Oliveira. A case of aggressive medulloblastoma with multiple recurrent chromosomal alterations. Cancer Genet Cytogenet.2010; 196:198-200.
21. Martin Gerard McCabe, Koichi Ichimura, et al.High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal Tumors. J Neuropathol Exp Neurol.2006; 65:549-561.
22. Rajeev Vibhakar, Beverly L. Davidson, Anup Madan.Adenoviral Mediated Re-Expression of Wnt Antagonist Dkk-1 Induces Apoptosis and Suppresses Tumor Growth in Medulloblastoma. Mol Ther.2006; 13:s363.
23. Yuan Lu, Sarra L. Ryan, David J. Elliott, Graham R. Bignell, P. Andrew Futreal, David W. Ellison,Simon Bailey, Steven C. Clifford. Amplification and Over-expression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in Medulloblastoma. PLoS ONE.2009; 4:e6159.
24. Pizer B, Clifford S.Medulloblastoma:new insights into biology and treatment. Arch Dis Child Educ Pract Ed.2008; 93:137-144.
25. Liang Yu,Diehn Maximilian, Bollen Andrew W.,Israel Mark A.,Gupta Nalin. Type Ⅰ collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. J Neurooncol.2008; 86:133-141.
26. Patrick Y.Wen, Santosh Kesari.Malignant Gliomas in Adults.N Engl J Med.2008; 359:492-507.
27. Huan J. Chang, Alison E. Burke, Richard M. Glass. Gliomas. JAMA.2010; 303:1000.
28. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, Holland EC.Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell.2010;6: 141-152.
29. Roel G.W. Verhaak,Katherine A. Hoadley，Elizabeth Purdom,Victoria Wang,Yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd Golub,Jill P. Mesirov, Gabriele Alexe,Michael Lawrence,et al.The Cancer Genome Atlas Research Network. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell.2010; 17:98-110.
30. Heiko Wurdak,Shoutian Zhu,Angelica Romero,Mihaela Lorger,James Watson, Chih-yuan Chiang,Jay Zhang,VanitaS.Natu,Luke L. Lairson,John R. Walker, Christopher M. Trussell,Griffith R. Harsh,Hannes Vogel,Brunhilde Felding-Habermann,Anthony P. Orth,Loren J. Miraglia,Daniel R. Rines,et al.An RNAi Screen Identifies TRRAP as a Regulator of Brain Tumor-Initiating Cell Differen-tiation. Cell Stem Cell.2010; 6:37-47.
31. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival:an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol.2008; 10:162-170.
32. Marc C. Chamberlain.10 questions about the use of bevacizumab in the manage-ment of recurrent malignant gliomas. The Neurologist.2010; 16:56-60.
33. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL,Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours.Nature. 2010; 463:318-325.
34. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A.,Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.2007; 21:2683-2710.
35. Jakub Godlewski，Michal O. Nowicki,Agnieszka Bronisz,Gerard Nuovo,Jeff Palatini,Michael De Lay,JamesVanBrocklyn,Michael C. Ostrowski,E. Antonio Chiocca, Sean E. Lawler. MicroRNA-451 Regulates LKB1/AMPK Signaling and Allows Adaptation to Metabolic Stress in Glioma Cells. Mol Cell.2010; 37:620-632.
36. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol.2007; 170:1445-1453.
37. Yoji Yamashita,Isao Kasugai,Masami Sato,Nobuhiro Tanuma,Ikuro Sato,Miyuki Nomura,Katsumi Yamashita,Yukihiko Sonoda,Toshihiro Kumabe, et al. CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples. J Neurooncol.2010; online.
38. Sathornssumetee S,Reardon DA,Desjardins A,Quinn JA,Vredenburgh JJ,et al. Molecularly targeted therapy for malignant glioma.Cancer.2007; 110:13-24.
39. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P,Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R,Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA,Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL,Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science.2008; 321:1807-1812.
40. Saad Z. Usmani, Robert Bona,Zihai Li.17 AAG for HSP90 Inhibition in Cancer-From Bench to Bedside. Curr Mol Med.2009; 9:654-664
41. Clark JC, Dass CR, Choong PF.Development of chondrosarcoma animal models for assessment of adjuvant therapy. ANZ J Surg.2009; 79:327-336.
42. Sui Xiong Cai, John Drewe,William Kemnitzer.Discovery of 4-Aryl-4H-Chromenes as Potent Apoptosis Inducers Using a Cell-and Caspase-Based Anti-Cancer Screening Apoptosis Program (ASAP):SAR Studies and the Identification of Novel Vascular Disrupting Agents. Anticancer Agents Med Chem.2009; 9:437-456.
43. Christophe Le Tourneau, J. Jack Lee, Lillian L. Siu. Dose Escalation Methods in Phase Ⅰ Cancer Clinical Trials. J Natl Cancer Inst.2009; 101:708-720.
44. Alfonso Quinta's-Cardama, Hagop Kantarjian, Jorge Cortes. Homoharringtonine, Omacetaxine Mepesuccinate, and Chronic Myeloid Leukemia Circa. Cancer.2009; 115:5382-5393.
45. Sandra E. Ghayad,Pascale A. Cohen. Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients. Recent Pat Anticancer Drug Discov.2010; 5:29-57.
46. Q.-B. Han, H.-X. Xu. Caged Garcinia Xanthones:Development Since 1937. Curr Med Chem..2009; 16:3775-3796.
47. Ken-Ichi Shinohara, Toshikazu Bando,Hiroshi Sugiyama. Anticancer activities of alkylating pyrrole-imidazole polyamides with specific sequence recognition. Anti-Cancer Drugs.2010; 21:228-242
48. Xianghui Ma, Zhiwen Wang. Anticancer drug discovery in the future:an evolutionary perspective. Drug Discov Today.2009; 14:1136-1142.
49. Sabine H. van Rijt, Peter J. Sadler. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today.2009; 14:1089-1097.
50. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell.1994; 77:63-71.
51. Sara Pensa,Christine J. Watson, Valeria Poli. Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer. J Mammary Gland Biol Neoplasia.2009; 14:121-129.
52. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature.2007; 448:1058-1062.
53. Sizhi Paul Gao, Kevin G. Mark, Kenneth Leslie, William Pao, Noriko Motoi, William L. Gerald, William D. Travis, William Bornmann, Darren Veach, Bayard Clarkson,Jacqueline F. Bromberg. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest.2007; 117:3846-3856.
54. Daniel J. Gough,Alicia Corlett,Karni Schlessinger,Joanna Wegrzyn, et al. Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation. Science.2009; 324:1713-1716.
55. Huaqi Jiang,Parthive H. Patel,Alexander Kohlmaier,Marc O. Grenley,Donald G. McEwen,and Bruce A. Edgar. Cytokine/Jak/Stat Signaling Mediates Regene-ration and Homeostasis in the Drosophila Midgut. Cell.2009; 137:1343-1355.
56. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007; 7:91-107.
57. Feng Huang, Xiaoyun Tong, Liangqing Fu, and Ronghua Zhang. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin.2008; 40:519-525.
58. Yu H., Kortylewski M, Pardoll D.. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev. Immunol.2007; 7, 41-51.
59. Marcin Kortylewski and Hua Yu. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol.2008; 20:228-233.
60. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature.2008; 454:436-44.
61. Joanna Wegrzyn,Ramesh Potla,Yong-Joon Chwae.Naresh B.V.Sepuri,Qifang Zhang,et al. Function of Mitochondrial Stat3 in Cellular Respiration. Science. 2009; 323:793-797.
62. Paolo Cinelli, Elisa A Casanoval, Syndi Uhligl, Priska Lochmatter,Takahiko Matsuda, Takashi Yokota, Thomas Riilicke, Birgit Ledermann, and Kurt Burki. Expression profiling in transgenic FVB/N embryonic stem cells overexpressing STAT3. BMC Dev Biol.2008; 8:1-17.
63. Marina Cella, Anja Fuchs, William Vermi, Fabio Facchetti, Karel Otero, Jochen K. M. Lennerz,Jason M. Doherty, Jason C. Mills,Marco Colonna. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity.Nature.2009; 457:722-725.
64. Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature.2007; 445:648-651.
65. Dae-Seop Shin,Hye-Nan Kim,Ki Deok Shin,Young Ju Yoon,Seung-Jun Kim,Dong Cho Han,Byoung-Mog Kwon.Cryptotanshinone Inhibits Constitutive Signal
Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells. Cancer Res.2009; 69:193-202.
66. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:a leading role for STAT3. Nat Rev Cancer.2009; 9:798-809.
67. Lilly Y. W. Bourguignonl, Karine Peyrollier, Weiliang Xia, and Eli Gilad. Hyaluronan-CD44 Interaction Activates Stem Cell Marker, Nanog. Stat-3-mediated MDR1 Gene Expression and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells. J Biol Chem.2008; 283:17635-17651.
68. Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, prolife-ration, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res.2009; 7:118-128.
69. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM.Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res.2009; 69:193-202.
70. Newman DJ. Natural products as leads to potential drugs:an old process or the new hope for drug discovery? J Med Chem.2008; 51:2589-2599.
71. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR. Establishment and characterization of four human medulloblastoma-derived cell lines.Oncol Res.1995;7:493-503.
72. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia.2005; 7:967-976.
73. Jung EM, Lee TJ, Park JW, Bae YS, Kim SH, Choi YH, Kwon TK.The novel phospholipase C activator, m-3M3FBS,induces apoptosis in tumor cells through caspase activation, down-regulation of XIAP and intracellular calcium signaling. Apoptosis 2008; 13:133-145.
74. Ben-Shlomo A, Miklovsky I, Ren SG, Yong WH, Heaney AP, Culler MD, Melmed S. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. J Clin Endocrinol Metab.2003; 88:858-863.
75. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN,Rorke LB, Brodeur GM, Phillips PC. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.Clin Cancer Res 2001; 7:2425-2433.
76. Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA,Kumar AP. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer:potential role for nexrutine. Neoplasia.2007; 9:893-899.
77. Simile MM, De Miglio MR, Muroni MR, Frau M, Asara G, Serra S, Muntoni MD, Seddaiu MA, Daino L, Feo F, et al. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis.2004; 25:333-341.
78. Li-Jun Yu, Mo-Li Wu, Hong Li, Xiao-Yan Chen,Qian Wang, Yuan Sun, Qing-You Kong,Jia Liu. Inhibition of STAT3 Expression and Signaling in Resveratrol-Differentiated Medulloblastoma Cells. Neoplasia.2008; 10:736-744.
79. Jeong-Yeh Yang, Mary Anne Della-Fera, Srujana Rayalam, Suresh Ambati, Diane L. Hartzell, Hea Jin Park,Clifton A. Baile. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci.2008; 82:1032-1039.
80. Hao Jiangl, Xia Shang, Hongtao Wu, Subhash C. Gautam, Shaza Al-Holou, Christina Li, Jarret Kuo, Lijie Zhang, and Michae Chopp. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol.2009; 8:25-33.
81. J.K. Kundu, Y.J. Surh, Cancer chemopreventive and therapeutic potential of resveratrol:mechanistic perspectives.Cancer Lett.2008; 269:243-261.
82. Hichem Sebai, Elodie Ristorcelli, Veronique Sbarra, Sonia Hovsepian, Guy Fayet, Ezzedine Aouani,Dominique Lombardo. Protective effect of resveratrol against LPS-induced extracellular lipoperoxidation in AR42J cells partly via a Myd88-dependent signaling pathway. Arch Biochem Biophys.2010; 495:56-61.
83. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate.2007; 67:1641-1653.
84. Hsieh TC.Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells. Asian J Androl.2009; 11:653-661.
85. Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S,Potter BV, Broggini M, Maffucci T. A novel inhibitor of the PI3K/Akt pathway based on
the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer.2010; 102:104-114.
86. Elisabeth M. Perchellet, Jean-Pierre H. Perchellet, Chanran K. Ganta, Deryl L. Troyer, Aibin Shi,Duy H. Hua. Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1-Oxopyrano[4,3-b] Benzopyrans and Nanogels for Drug Delivery. Anticancer Agents Med Chem.2009;9:864-876.
87. Christophe Rochais, Patrick Dallemagne, Sylvain Rault. Tripentones:A Promising Series of Potent Anti-Cancer Agents. Anticancer Agents Med Chem. 2009;9:369-380.
88. Arkenau HT. Gastric cancer in the era of molecularly targeted agents:current drug development strategies. J Cancer Res Clin Oncol.2009; 135:855-866.
89. D.J.Gough, A.Corlett, K Schlessinger, J.Wegrzyn, A.C.Larner,D.E.Levy. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009; 324:1713-1716.
90. S J Baker, S G Rane, E P Reddy. Hematopoietic cytokine receptor signaling. Oncogene.2007; 26:6724-6737.
91. Grivennikov S., Karin M. Autocrine IL-6 signaling:a key event in tumourigenesis? Cancer Cell.2008; 13:7-9.
92. Sandra Rebouissou, Mohamed Amessou, Gabrielle Couchy, Karine Poussin, Sandrine Imbeaud,Camilla Pilati, Tina Izard, Charles Balabaud,et al.Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.Nature.2009; 457:200-205.
93. Rigby R.J.,Simmons J.G.,Greenhalgh C.J.,et al.Suppressor of cytokine signaling 3(SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in thecolon. Oncogene.2007; 26:4833-4841.
94. Ping Li,Chang Tong,Ruty Mehrian-Shai,Li Jia,Nancy Wu,Youzhen Yan,Robert E. Maxson,Eric N. Schulze,HouyanSong,Chih-Lin Hsieh,Martin F. Pera,Qi-Long Ying. Germline Competent Embryonic Stem Cells Derived from Rat Blastocysts. Cell.2008; 135:1299-1310.
95. Ryan Conderl and Juergen A. Knoblichl. Fly stem cell Research Gets Infectious. Cell.2009; 137:1185-1187.
96. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S,Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood.2007; 109:2293-2302.
97. Lu X.,Chen J., Sasmono R.T., His E.D., Sarosiek K.A., et al.T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol.Cell. Biol.2007; 27:2166-2179.
98. Ben J. Shields, Christine Hauser,Patricia E. Bukczynska, Naomi W. Court,and Tony Tiganis. DNA Replication Stalling Attenuates TyrosineKinase Signaling to Suppress S Phase Progression. Cancer Cell.2008; 14:166-179.
99. Li J, Piao YF, Jiang Z, Chen L, Sun HB. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J Gas-troenterol.2009; 15:2602-2608.
100. Torres L, Sandoval J, Penella E, Zaragoza R, Garcia C, Rodriguez JL, Vina JR, Garcia-Trevijano ER. In vivo GSH depletion induces c-myc expression by modulation of chromatin protein complexes. Free Radic Biol Med.2009; 46: 1534-1542.
101. Jinhai Gu,Gang Li,Tao Sun,Yuhang Su,Xulong Zhang, Jie Shen, Zhigang Tian, Jian Zhang. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant gliomacells. J Neurooncol.2008; 89:9-17.
102. Qiu Z,Huang C,Sun J,Qiu W,Zhang J,Li H,Jiang T,Huang K,Cao J. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci.2007; 98:1099-1106.
103. Sandrine Ruchaud, Mar Carmena, William C. Earnshaw. The Chromosomal Passenger Complex:One for All and All for One. Cell.2007;131:230-231.
104. Christian Pohl, Stefan Jentsch. Final Stages of Cytokinesis and Midbody Ring Formation Are Controlled by BRUCE. Cell.2008; 132:832-845.
105. Sergei I. Grivennikov,Florian R. Greten,Michael Karin. Immunity, Inflammation, and Cancer. Cell.2010; 140:883-899.
106. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res.2008; 314:1163-1176.
107. Da Costa SV, Roela RA, Junqueira MS, Arantes C, Brentani MM. The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes. Leuk Res.2010;34:507-12.
108. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al.. Thelandscape of somatic copy-number alteration across human cancers. Nature.2010; 463: 899-905.
109. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA. c-Myc regulates transcriptional pause release. Cell.2010; 141:432-445.
110. Dai CH, Li J, Shi SB, Yu LC, Ge LP, Chen P. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol.2010; 40:327-335.
111. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, Papadaki H. Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol.2010; 25:299-307.
112. Liu XA, Liao K, Liu R, Wang HH, Zhang Y, Zhang Q, Wang Q, et al. Tau dephosphorylation potentiates apoptosis by mechanisms involving a failed dephosphorylation/activation of Bcl-2. J Alzheimers Dis.2010; 19:953-962.
113.Absalan F, Movahedin M, Mowla SJ. Germ cell apoptosis induced by experimental cryptorchidism is mediated by molecular pathways in mouse testis. Andrologia.2010;42:5-12.
114. Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int.2007; 7:4.
115. Ge KL, Chen WF, Xie JX, Wong MS. Ginsenoside Rgl protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways. J Ethnopharmacol.2010; 127:118-123.
116. Jie Yang, Xuesong Liu, Kapil Bhalla, Caryn Naekyung Kim, Ana Maria Ibrado, Jiyang Cai, Tsung-I Peng, Dean P. Jones, Xiaodong Wang. Prevention of Apoptosis by Bcl-2:Release of Cytochrome c from Mitochondria Blocked. Science.1997; 275:1129-1132.
117. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foa R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia.2009; 11:720-731.
118. Jie Yang, Xuesong Liu, Kapil Bhalla, Caryn Naekyung Kim, Ana Maria Ibrado, Jiyang Cai, Tsung-Ⅰ Peng, Dean P. Jones, Xiaodong Wang. Prevention of Apoptosis by Bcl-2:Release of Cytochrome c from Mitochondria Blocked. Science.1997; 275:1129-1132.
119. Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, Jeong HG. Bisphenol A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol Lett.2010; 193:200-208.
120. Rosa Sirianni, Adele Chimento, Arianna De Luca, Fabiana Zolea, Amalia Carpino, Vittoria Rago, Marcello Maggiolini, et al. Inhibition of Cyclo-oxygenase-2 Down-regulates Aromatase Activity and Decreases Proliferation of Leydig Tumor Cells. J Biol Chem.2009; 284:28905-28916.
121. Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvⅢ-STAT3 signaling axes. Cancer Res.2010; 8:232-245.
122.Kwak HJ, Park KM, Choi HE, Park HY. Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells:role of PKC and COX-2. Free Radic Res.2009;43:744-752.